Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies

References

• Pasquini M, Wang Z. Current use and outcome of hematopoietic stem cell transplantation: part II – CIBMTR Summary Slides 2009. CIBMTR Newsletter [Serial Online]15(2), 7–11 (2009).
   Google Scholar
• Storb R, Yu C, Wagner JL et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood89(8), 3048–3054 (1997).
   PubMed Web of Science ®Google Scholar
• Yu C, Storb R, Mathey B et al. DLA-identical bone marrow grafts after low-dose total body irradiation: effects of high-dose corticosteroids and cyclosporine on engraftment. Blood86(11), 4376–4381 (1995).
   PubMed Web of Science ®Google Scholar
• Slavin S, Gottlieb M, Strober S et al. Transplantation of bone marrow in outbred dogs without graft-versus-host disease using total lymphoid irradiation. Transplantation27(2), 139–142 (1979).
   Google Scholar
• Slavin S, Strober S, Fuks Z, Kaplan HS. Long-term survival of skin allografts in mice treated with fractionated total lymphoid irradiation. Science193(4259), 1252–1254 (1976).
   PubMed Web of Science ®Google Scholar
• Slavin S, Strober S, Fuks Z, Kaplan HS. Induction of specific tissue transplantation tolerance using fractionated total lymphoid irradiation in adult mice: long-term survival of allogeneic bone marrow and skin grafts. J. Experimental Med.146(1), 34–48 (1977).
   PubMed Web of Science ®Google Scholar
• Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood89(12), 4531–4536 (1997).
   PubMed Web of Science ®Google Scholar
• Valcarcel D, Martino R, Caballero D et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J. Clin. Oncol.26(4), 577–584 (2008).
   PubMed Web of Science ®Google Scholar
• Mohty M, de Lavallade H, El-Cheikh J et al. Reduced intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia: long term results of a ‘donor’ versus ‘no donor’ comparison. Leukemia23(1), 194–196 (2009).
   PubMed Web of Science ®Google Scholar
• Goldstein S, Luger S. Concepts and controversies in the use of novel preparative regimens for allogeneic stem cell transplantation. In: Allogeneic Stem Cell Transplantation. (2nd edition). Lazarus H, Lauglin MJ (Eds). Humana Press, NJ USA (2010).
   Google Scholar
• Bacigalupo A, Ballen K, Rizzo D et al. Defining the intensity of conditioning regimens: working definitions. Biol. Blood Marrow Transplantat.15(12), 1628–1633 (2009).
   PubMed Web of Science ®Google Scholar
• Hartman AR, Williams S, Dillon JJ. Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs total body irradiation: a meta-analysis. Bone Marrow Transplant.22, 439–443 (1998).
   PubMed Web of Science ®Google Scholar
• Socie G, Clift RA, Blaise D et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood98(13), 3569–3574 (2001).
   PubMed Web of Science ®Google Scholar
• Blaise D, Maraninchi D, Archimbaud E. Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan–cytoxan versus cytoxan–total body irradiation as preparative regimen: a report from the Groupe d’Etudes de la Greffe de Moelle Osseuse. Blood79, 2578–2582 (1992).
   PubMed Web of Science ®Google Scholar
• Ringden O, Ruutu T, Remberger M. A randomized trial of comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia – a report from the Nordic Bone Marrow Transplantation Group. Blood83, 2723–2730 (1994).
   PubMed Web of Science ®Google Scholar
• Clift RA, Buckner CD, Thomas ED et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood84(6), 2036–2043 (1994).
   PubMed Web of Science ®Google Scholar
• Devergie A, Blaise D, Attal M. Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan–cytoxan versus cytoxan–total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft. Blood85, 2263–2268 (1995).
   PubMed Web of Science ®Google Scholar
• Litzow MR, Perez WS, Klein JP et al. Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide–total body irradiation versus busulphan–cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission. Br. J. Haematol.119(4), 1115–1124 (2002).
   PubMed Web of Science ®Google Scholar
• Russell J, Tran HT, Quinlan D et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol. Blood Marrow Transplant.8, 468–476 (2002).
   PubMed Web of Science ®Google Scholar
• deLima M, Couriel D, Thall PF. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood104, 857–864 (2004).
   Google Scholar
• Bornhauser M, Storer B, Slattery J et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood102, 820–826 (2003).
   PubMed Web of Science ®Google Scholar
• Field T, Perkins J, Alsina M, Anasetti C. Busulfan area-under-the-curve finding study within a busulfan/fludarabine (BuFlu) conditioning regimen before allogeneic hematopoietic cell transplantation. Blood108, 832a (2006).
   Google Scholar
• Shimoni A, Hardan I, Shem-Tov N et al. Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan. Leukemia21(10), 2109–2116 (2007).
   PubMed Web of Science ®Google Scholar
• van Besien K, Artz A, Smith S et al. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J. Clin. Oncol.23(24), 5728–5738 (2005).
   PubMed Web of Science ®Google Scholar
• Sayer HG, Kroger M, Beyer J et al. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant.31(12), 1089–1095 (2003).
   PubMed Web of Science ®Google Scholar
• de Lima M, Anagnostopoulos A, Munsell M et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood104(3), 865–872 (2004).
   PubMed Web of Science ®Google Scholar
• Kebriaei P, Kline J, Stock W et al. Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes. Bone Marrow Transplant.35(10), 965–970 (2005).
   PubMed Web of Science ®Google Scholar
• Shimoni A, Hardan I, Shem-Tov N et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia20(2), 322–328 (2006).
   PubMed Web of Science ®Google Scholar
• Aoudjhane M, Labopin M, Gorin NC et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia19(12), 2304–2312 (2005).
   PubMed Web of Science ®Google Scholar
• Perez-Simon JA, Diez-Campelo M, Martino R et al. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation. Br. J. Haematol.130(3), 394–403 (2005).
   PubMed Web of Science ®Google Scholar
• Massenkeil G, Nagy M, Neuburger S et al. Survival after reduced-intensity conditioning is not inferior to standard high-dose conditioning before allogeneic haematopoietic cell transplantation in acute leukaemias. Bone Marrow Transplant.36(8), 683–689 (2005).
   Google Scholar
• Bacigalupo A, Lamparelli T, Barisione G et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol. Blood Marrow Transplant.12(5), 560–565 (2006).
   PubMed Web of Science ®Google Scholar
• Maruyama D, Fukuda T, Kato R et al. Comparable antileukemia/lymphoma effects in nonremission patients undergoing allogeneic hematopoietic cell transplantation with a conventional cytoreductive or reduced-intensity regimen. Biol. Blood Marrow Transplant.13(8), 932–941 (2007).
   Google Scholar
• Scott BL, Sandmaier BM, Storer B et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia20(1), 128–135 (2006).
   PubMed Web of Science ®Google Scholar
• Alyea EP, Kim HT, Ho V et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood105(4), 1810–1814 (2005).
   PubMed Web of Science ®Google Scholar
• Hari P, Carreras J, Zhang MJ et al. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol. Blood Marrow Transplant.14(2), 236–245 (2008).
   PubMed Web of Science ®Google Scholar
• Ringden O, Labopin M, Ehninger G et al. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J. Clin. Oncol.27(27), 4570–4577 (2009).
   PubMed Web of Science ®Google Scholar
• Ferrara J, Deeg H. Graft-versus-host disease. N. Engl. J. Med.324, 667–674 (1991).
   PubMed Web of Science ®Google Scholar
• Mielcarek M, Martin PJ, Leisenring W et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood102(2), 756–762 (2003).
   PubMed Web of Science ®Google Scholar
• Sorror M, Maris M, Diaconescu R, Storb R. Lessened severe graft-versus-host after ‘minitransplantations’. Blood105(6), 2614 (2005).
   PubMed Web of Science ®Google Scholar
• Couriel DR, Saliba RM, Giralt S et al. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol. Blood Marrow Transplant.10(3), 178–185 (2004).
   PubMed Web of Science ®Google Scholar
• Shlomchik W, Couzens M, Tang C et al. Prevention of graft-versus-host disease by inactivation of host antigen-presenting cells. Science285 (1999).
   Google Scholar
• Mielcarek M, Storb R. Graft-vs-host disease after non-myeloablative hematopoietic cell transplantation. Leuk. Lymphoma46(9), 1251–1260 (2005).
   PubMed Web of Science ®Google Scholar
• Mielcarek M, Burroughs L, Leisenring W et al. Prognostic relevance of ‘early-onset’ graft-versus-host disease following non-myeloablative haematopoietic cell transplantation. Br. J. Haematol.129(3), 381–391 (2005).
   PubMed Web of Science ®Google Scholar
• Levine J, Uberti J, Ayash L et al. Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy. Biol. Blood Marrow Transplant.9, 189–197 (2003).
   PubMed Web of Science ®Google Scholar
• Couriel D, Giralt S. Graft vs host disease in nonmyeloablative transplant In: Graft vs Host Disease. Ferrara JL, Cooke KR, Deeg HJ (Eds). Marcel Dekker, NY, USA (2005).
   Google Scholar
• Loren AW, Luger SM, Stadtmauer EA et al. Intensive graft-versus-host disease prophylaxis is required after unrelated-donor nonmyeloablative stem cell transplantation. Bone Marrow Transplant.35(9), 921–926 (2005).
   Google Scholar
• McSweeney PA, Niederwieser D, Shizuru JA et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood97(11), 3390–3400 (2001).
   PubMed Web of Science ®Google Scholar
• Maris MB, Niederwieser D, Sandmaier BM et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood102(6), 2021–2030 (2003).
   PubMed Web of Science ®Google Scholar
• Hegenbart U, Niederwieser D, Sandmaier BM et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J. Clin. Oncol.24(3), 444–453 (2006).
   PubMed Web of Science ®Google Scholar
• Schetelig J, Bornhauser M, Schmid C et al. Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group. J. Clin. Oncol.26(32), 5183–5191 (2008).
   PubMed Web of Science ®Google Scholar
• Hale G, Zhang MJ, Bunjes D et al. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood92(12), 4581–4590 (1998).
   PubMed Web of Science ®Google Scholar
• Hale G, Cobbold S, Waldmann H. T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation. Transplantation45(4), 753–759 (1988).
   PubMed Web of Science ®Google Scholar
• Kottaridis PD, Milligan DW, Chopra R et al.In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood96(7), 2419–2425 (2000).
   PubMed Web of Science ®Google Scholar
• Perez-Simon JA, Kottaridis PD, Martino R et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood100(9), 3121–3127 (2002).
   PubMed Web of Science ®Google Scholar
• Morris EC, Rebello P, Thomson KJ et al. Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications. Blood102(1), 404–406 (2003).
   PubMed Web of Science ®Google Scholar
• Morris E, Thomson K, Craddock C et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood104(13), 3865–3871 (2004).
   PubMed Web of Science ®Google Scholar
• Michaelis L, Lin S, Joseph L et al. Chimerism does not predict for outcome after alemtuzumab based conditioning. Bone Marrow Transplant.40(2), 181 (2007).
   PubMed Web of Science ®Google Scholar
• Juliusson G, Theorin N, Karlsson K, Frodin U, Malm C. Subcutaneous alemtuzumab vs ATG in adjusted conditioning for allogeneic transplantation: influence of Campath dose on lymphoid recovery, mixed chimerism and survival. Bone Marrow Transplant.37(5), 503–510 (2006).
   PubMed Web of Science ®Google Scholar
• Hale G, Cobbold S, Novitzky N et al. Campath-1 antibodies in stem-cell transplantation. Cytotherapy3(3), 145–164 (2001).
   PubMed Web of Science ®Google Scholar
• Klangsinsirikul P, Carter GI, Byrne JL, Hale G, Russell NH. Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution. Blood99(7), 2586–2591 (2002).
   PubMed Web of Science ®Google Scholar
• Ratzinger G, Reagan JL, Heller G, Busam KJ, Young JW. Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation. Blood101(4), 1422–1429 (2003); erratum in Blood105(8), 3018 (2003).
   PubMed Web of Science ®Google Scholar
• Khouri IF, Albitar M, Saliba RM et al. Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics. Bone Marrow Transplant.33(8), 833–837 (2004).
   PubMed Web of Science ®Google Scholar
• Rebello P, Cwynarski K, Varughese M, Eades A, Apperley JF, Hale G. Pharmacokinetics of CAMPATH-1H in BMT patients. Cytotherapy3(4), 261–267 (2001).
   PubMed Web of Science ®Google Scholar
• Hale G, Rebello P, Brettman LR et al. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood104(4), 948–955 (2004).
   PubMed Web of Science ®Google Scholar
• Russell NH, Byrne JL. In vivo Campath for the prevention of GvHD following allogeneic HSCT: effects of dose, schedule and antibody type. Bone Marrow Transplant.34(12), 1101–1102 (2004).
   Google Scholar
• Lan F, Zeng D, Higuchi M, Higgins JP, Strober S. Host conditioning with total lymphoid irradiation and antithymocyte globulin prevents graft-versus-host disease: the role of CD1-reactive natural killer T cells. Biol. Blood Marrow Transplant.9(6), 355–363 (2003).
   PubMed Web of Science ®Google Scholar
• Lan F, Zeng D, Higuchi M, Huie P, Higgins JP, Strober S. Predominance of NK1.1+TCR a b+ or DX5+TCR a b+ T cells in mice conditioned with fractionated lymphoid irradiation protects against graft-versus-host disease: ‘natural suppressor’ cells. J. Immunol.167(4), 2087–2096 (2001).
   PubMed Web of Science ®Google Scholar
• Lowsky R, Takahashi T, Liu YP et al. Protective conditioning for acute graft-versus-host disease. N. Engl. J. Med.353(13), 1321–1331 (2005); erratum in N. Engl. J. Med.354(8), 884 (2006).
   PubMed Web of Science ®Google Scholar
• Kohrt HE, Turnbull BB, Heydari K et al. TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood114(5), 1099–1109 (2009).
   PubMed Web of Science ®Google Scholar
• Kolb H, Schmid C, Barrett AJ, Schende D. Graft versus leukemia reactions in allogeneic chimeras. Blood103, 767–776 (2004).
   PubMed Web of Science ®Google Scholar
• Shlomchik WD. Graft-versus-host disease. Nat. Rev. Immunol.7(5), 340–352 (2007).
   PubMed Web of Science ®Google Scholar
• Ferrara J, Cooke K, Deeg H (Eds). Graft vs Host Disease (Third Edition). Marcel Dekker, NY, USA (2005).
   Google Scholar
• Barrett AJ. Understanding and harnessing the graft-versus-leukaemia effect. Br. J. Haematol.142(6), 877–888 (2008).
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Capanni M, Urbani E et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science295(5562), 2097–2100 (2002).
   PubMed Web of Science ®Google Scholar
• Ruggieri L, Capanni M, Martelli M, Velardi A. Cellular therapy: exploiting NK cell alloreactivity in transplantation. Curr. Opin. Hematol.8, 355–359 (2001).
   Google Scholar
• Brooks A, Boyington J, Sun P. Natural killer cell recognition of HLA class I molecules. Rev. Immunogenet.2, 433–448 (2000).
   Google Scholar
• Davies S, Ruggieri L, DeFor T et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Blood100, 3825–3827 (2002).
   PubMed Web of Science ®Google Scholar
• Giebel S, Locatelli F, Lamparelli T et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood102, 8 (2003).
   Google Scholar
• Chen C, Busson M, Rocha V et al. Activating KIR genes are associated with CMV reactivation and survival after non-T-cell depleted HLA-identical sibling bone marrow transplantation for malignant disorders. Bone Marrow Transplant.38, 437–444 (2006).
   PubMed Web of Science ®Google Scholar
• Verhyden S, Schots R, Duquet W, Demanet C. A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation. Leukemia19, 1446–1451 (2005).
   Google Scholar
• Savani BN, Mielke S, Adams S et al. Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia. Leukemia21(10), 2145–2152 (2007).
   PubMed Web of Science ®Google Scholar
• Rapaport A, Stadtmauer E, Aqui N et al. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat. Med.11(11), 1230–1237 (2005).
   Google Scholar
• Rapoport A, Stadtmauer E, Levine B et al. Adoptive transfer of ex vivo costimulated autologous T cells in conjunction with pneumococcal conjugate vaccine immunization for myeloma: results of a randomized study. Blood104, 128a (2004).
   Google Scholar
• Rezvani K, Yong ASM, Savani BN et al. Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. Blood110(6), 1924–1932 (2007).
   PubMed Web of Science ®Google Scholar
• Rezvani K, Yong A, Mielke S et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 andWT1 peptide vaccination in patients with myeloid malignancies. Blood111, 236–242 (2008).
   PubMed Web of Science ®Google Scholar
• Rusakiewicz S, Molldrem JJ. Immunotherapeutic peptide vaccination with leukemia-associated antigens. Curr. Opin. Immunol.18(5), 599–604 (2006).
   PubMed Web of Science ®Google Scholar
• Porter D, Collins R, Drobyski W, Connors J, Van Hoef M, Antin J. Long-term follow-up of 55 patients who achieved complete remission (CR) after donor leukocyte infusions (DLI) for relapse after allogeneic bone marrow transplantation (BMT). Blood90, 549a (1997).
   Google Scholar
• Collins R, Shpilberg O, Drobyski W et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J. Clin. Oncol.15, 433–444 (1997).
   PubMed Web of Science ®Google Scholar
• Drobyski W, Keever C, Roth M et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood82(8), 2310–2318 (1993).
   PubMed Web of Science ®Google Scholar
• Kolb H, Schattenberg A, Goldman J et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood86, 2041–2050 (1995).
   PubMed Web of Science ®Google Scholar
• Mackinnon S, Hows J, Goldman J. Induction of in vitro graft-versus-leukemia activity following bone marrow transplantation for chronic myeloid leukemia. Blood76, 2037–2045 (1990).
   PubMed Web of Science ®Google Scholar
• Porter D, Collins R, Hardy C et al. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood95, 1214–1221 (2000).
   PubMed Web of Science ®Google Scholar
• Loren AW, Porter DL. Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation. Bone Marrow Transplant.41(5), 483–493 (2008).
   PubMed Web of Science ®Google Scholar
• Levine J, Braun T, Penza S et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem cell transplantation. J. Clin. Oncol.20, 405–412 (2002).
   PubMed Web of Science ®Google Scholar
• Porter D, Roth M, McGarigle C, Ferrara J, Antin J. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N. Engl. J. Med.330, 100–106 (1994).
   PubMed Web of Science ®Google Scholar
• Bishop MR, Dean RM, Steinberg SM et al. Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation. Ann. Oncol.19(11), 1935–1940 (2008).
   PubMed Web of Science ®Google Scholar
• Peggs KS, Hunter A, Chopra R et al. Clinical evidence of a graft-versus-Hodgkin’s-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet365(9475), 1934–1941 (2005).
   PubMed Web of Science ®Google Scholar
• Porter D, Roth M, Lee S, McGarigle C, Ferrara J, Antin J. Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation. Bone Marrow Transplant.18, 975–980 (1996).
   PubMed Web of Science ®Google Scholar
• Szer J, Grigg A, Phillipos G, Sheridan W. Donor leukocyte infusions after chemotherapy for patients relapsing with acute leukaemia following allogeneic BMT. Bone Marrow Transplant.11, 109–111 (1993).
   PubMed Web of Science ®Google Scholar
• Collins RH Jr, Goldstein S, Giralt S et al. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant.26(5), 511–516 (2000).
   PubMed Web of Science ®Google Scholar
• Zeiser R, Bertz H, Spyridonidis A, Houet L, Finke J. Donor lymphocyte infusions for multiple myeloma: clinical results and novel perspectives. Bone Marrow Transplant.34(11), 923–928 (2004).
   PubMed Web of Science ®Google Scholar
• Peggs K, Mackinnon S. Graft-versus-myeloma: are durable responses a clinical reality following donor lymphocyte infusion? Leukemia18(9), 1541–1542; author reply 1542–1543 (2004).
   PubMed Web of Science ®Google Scholar
• Ayuk F, Shimoni A, Nagler A et al. Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma. Leukemia18(3), 659–662 (2004).
   PubMed Web of Science ®Google Scholar
• Mandigers CMPW, Verdonck LF, Meijerink JPP, Dekker AW, Schattenberg AVMB, Raemaekers JMM. Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation. Bone Marrow Transplant.32(12), 1159–1163 (2003).
   PubMed Web of Science ®Google Scholar
• Russell NH, Byrne JL, Faulkner RD, Gilyead M, Das-Gupta EP, Haynes AP. Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplant.36(5), 437–441 (2005).
   PubMed Web of Science ®Google Scholar
• Peggs KS, Thomson K, Hart DP et al. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood103(4), 1548–1556 (2004).
   PubMed Web of Science ®Google Scholar
• Porter D, Levine B, Bunin N et al. A Phase I trial of donor lymphocyte infusions expanded and activated ex-vivo via CD3/CD28 co-stimulation. Blood107(4), 1325–1331 (2006).
   PubMed Web of Science ®Google Scholar
• Pan L, Teshima T, Hill GR et al. Granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation maintains graft-versus-leukemia effects through a perforin-dependent pathway while preventing graft-versus-host disease. Blood93(12), 4071–4078 (1999).
   PubMed Web of Science ®Google Scholar
• Arpinati M, Green CL, Heimfeld S, Heuser JE, Anasetti C. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood95(8), 2484–2490 (2000).
   PubMed Web of Science ®Google Scholar
• Beatty GL, Smith JS, Reshef R et al. Functional unresponsiveness and replicative senescence of myeloid leukemia antigen-specific CD8+ T cells after allogeneic stem cell transplantation. Clin. Cancer Res.15(15), 4944–4953 (2009).
   PubMed Web of Science ®Google Scholar
• Mackinnon S, Papadopoulos E, Carabasi M et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood86, 1261–1268 (1995).
   PubMed Web of Science ®Google Scholar
• Mackinnon S, Papadopoulos E, Carabasi M, Reich L, Collins N, O’Reilly R. Adoptive Immunotherapy using donor leukocytes following bone marrow transplantation for chronic myeloid leukemia: is T cell dose important in determining biological response? Bone Marrow Transplant.15, 591–594 (1995).
   PubMed Web of Science ®Google Scholar
• Barrett AJ, Mavroudis D, Tisdale J et al. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect. Bone Marrow Transplant.21(6), 543–551 (1998).
   PubMed Web of Science ®Google Scholar
• Kolb H, Mittermuller J, Clemm C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood76, 2462–2465 (1990).
   PubMed Web of Science ®Google Scholar
• Bellucci R, Alyea EP, Weller E et al. Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma. Blood99(12), 4610–4617 (2002).
   PubMed Web of Science ®Google Scholar
• Schleuning M, Schmid C, Ledderose G et al. Durable remission after prophylatic donor lymphocyte transfusion following allogeneic stem cell transplantation with reduced conditioning for high-risk AML and MDS. Blood104(11), 89a (2004).
   Google Scholar
• Arnold R, Lutz C, Neuburger S et al. Allogeneic stem cell transplantation in adult all: does prophylactic donor lymphocyte infusion (DLI) improve survival? Biol. Blood Marrow Transplant.11(2), 2a (2005).
   Google Scholar
• Varela-Rohena A, Carpenito C, Perez EE et al. Genetic engineering of T cells for adoptive immunotherapy. Immunol. Res.42(1–3), 166–81 (2008).
   PubMed Web of Science ®Google Scholar
• Sadelain M, Brentjens R, Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Curr. Opin. Immunol.21(2), 215–223 (2009).
   PubMed Web of Science ®Google Scholar
• Chakraverty R, Sykes M. The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemia. Blood110(1), 9–17 (2007).
   PubMed Web of Science ®Google Scholar
• Reddy P, Maeda Y, Liu C, Krijanovski OI, Korngold R, Ferrara JL. A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses. Nat. Med.11(11), 1244–1249 (2005).
   PubMed Web of Science ®Google Scholar
• Mapara MY, Kim Y-M, Wang S-P, Bronson R, Sachs DH, Sykes M. Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells. Blood100(5), 1903–1909 (2002).
   PubMed Web of Science ®Google Scholar
• Chakraverty R, Eom H-S, Sachs J et al. Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions. Blood108(6), 2106–2113 (2006).
   PubMedGoogle Scholar
• Cohen JL, Trenado A, Vasey D, Klatzmann D, Salomon BL. CD4(+)CD25(+) immunoregulatory T cells: new therapeutics for graft-versus-host disease. J. Experimental Med.196(3), 401–406 (2002).
   PubMed Web of Science ®Google Scholar
• Earle KE, Tang Q, Zhou X et al.In vitro expanded human CD4+CD25+ regulatory T cells suppress effector T cell proliferation. Clin. Immunol.115(1), 3–9 (2005).
   PubMed Web of Science ®Google Scholar
• Riley JL, June CH, Blazar BR. Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity30(5), 656–665 (2009).
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Chesney J, Curriel TJ. Emerging strategies in regulatory T-cell immunotherapies. Clin. Adv. Hematol. Oncol.7(1), 1–10; quiz 11–12 (2009).
   PubMedGoogle Scholar
• Di Ianni M, Falzetti F, Carotti A et al. Adoptive Immunotherapy with Tregs prevents GvHD and favours immune reconstitution after HLA haploidentical transplants for hematological malignancies. Blood (ASH Annual Meeting Abstracts)114(22), 4 (2009).
   Google Scholar
• Lowsky R, Takahashi T, Liu YP et al. Protective conditioning for acute graft-versus-host disease. N. Engl. J. Med.353(13), 1321–1331 (2005).
   PubMed Web of Science ®Google Scholar
• Miller JS, Soignier Y, Panoskaltsis-Mortari A et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood105(8), 3051–3057 (2005).
   PubMed Web of Science ®Google Scholar
• Baron F, Beguin Y. Preemptive cellular immunotherapy after T-cell-depleted allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant.8, 351–359 (2002).
   PubMed Web of Science ®Google Scholar
• Massenkeil G, Nagy M, Lawang M et al. Reduced intensity conditioning and prophylactic DLI can cure patients with high-risk acute leukaemias if complete donor chimerism can be achieved. Bone Marrow Transplant.31(5), 339–345 (2003).
   PubMed Web of Science ®Google Scholar
• Montero A, Savani BN, Shenoy A et al. T-cell depleted peripheral blood stem cell allotransplantation with T-cell add-back for patients with hematological malignancies: effect of chronic GVHD on outcome. Biol. Blood Marrow Transplantat.12(12), 1318–1325 (2006).
   PubMed Web of Science ®Google Scholar
• Barrett AJ, Rezvani K. Translational mini-review series on vaccines: peptide vaccines for myeloid leukaemias. Clin. Experimental Immunol.148(2), 189–198 (2007).
   PubMed Web of Science ®Google Scholar
• Rossig C, Brenner MK. Genetic modification of T lymphocytes for adoptive immunotherapy. Mol. Ther.10(1), 5–18 (2004).
   PubMed Web of Science ®Google Scholar
• Valcarcel D, Martino R, Sureda A et al. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies. Eur. J. Haematol.74(2), 144–151 (2005).
   PubMed Web of Science ®Google Scholar
• Martino R, Iacobelli S, Brand R et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood108(3), 836–846 (2006).
   PubMed Web of Science ®Google Scholar
• Martino R, Caballero MD, Simon JA et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood100(6), 2243–2245 (2002).
   PubMed Web of Science ®Google Scholar